Retention of activity by the new generation platinum agent AMD0473 in four human tumour cell lines possessing acquired resistance to oxaliplatin

European Journal of Cancer

Volumn 38, Issue 17, 2002, Pages 2309-2315

  Sharp, S Y ^a   O'Neill, C F ^a   Rogers, P ^a   Boxall, F E ^a   Kelland, L R ^a,b  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Circumvention; Mismatch repair; Oxaliplatin; Resistance; ZD0473

Indexed keywords

AMD 0473; BBR 3464; CISPLATIN; OXALIPLATIN; PLATINUM DERIVATIVE;

ARTICLE; CANCER CELL CULTURE; CANCER RESISTANCE; CELL STRAIN HT29; COLON CARCINOMA; CONTROLLED STUDY; DNA ADDUCT; DRUG ACTIVITY; DRUG SENSITIVITY; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; MEMBRANE TRANSPORT; MISMATCH REPAIR; OVARY CARCINOMA; PRIORITY JOURNAL; PROBABILITY; REDUCTION; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; CELL DIVISION; COLONIC NEOPLASMS; DNA, NEOPLASM; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MALE; ORGANOPLATINUM COMPOUNDS; OVARIAN NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 0036849436     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(02)00244-7     Document Type: Article

References (31)

1. Kelland L.R., Sharp S.Y. Platinum compounds in cancer therapy. Curr Opin Oncol, Endocrine, Metabolic Invest Drugs. 1:1999;380-385.
2. Judson I., Kelland L.R. New developments and approaches in the platinum arena. Drugs. 59:2000;29-36.
3. Machover D., Diaz-Rubio E., de Gramont A.et al. Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines. Ann. Oncol. 7:1996;95-98.
4. Becouarn Y., Ychou M., Ducreux M.et al. Phase II trial of oxaliplatin as first-line chemotherapy in metastatic colorectal cancer patients. J. Clin. Oncol. 16:1998;2739-2744.
5. Armand J.-P., Boige V., Raymond E.et al. Oxaliplatin in colorectal cancer. an overview Seminars Oncology. 27:2000;96-104.
6. Piccart M.J., Green J.A., Lacave A.J.et al. Oxaliplatin or paclitaxel in patients with platinum-pretreated advanced ovarian cancer. a randomized phase II of the European Organization for Research and Treatment of Cancer Gynecology Group J. Clin. Oncol. 18:2000;1193-1202.
7. Rixe O., Ortuzar W., Alvarez M.et al. Oxaliplatin, tetraplatin, cisplatin, and carboplatin. spectrum of activity in drug-resistant cell lines and in cell lines of the National Cancer Institute's Anticancer drug screen panel Biochem. Pharmacol. 52:1996;1855-1865.
8. Kelland L., Judson I., Koehler M., Stephens T., Roberts D. Preclinical and clinical overview of the novel platinum complex, ZD0473 (cis-amminedichloro [2-methylpyridine] platinum (II). Lung Cancer. 29:2000.
9. Raynaud F.I., Boxall F.E., Goddard P.M.et al. Cis-amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex. in vivo activity, toxicology and pharmacokinetics in mice Clin. Cancer Res. 3:1997;2063-2074.
10. Holford J., Sharp S.Y., Murrer B.A., Abrams M., Kelland L.R. In vitro circumvention of cisplatin-resistance by the novel sterically hindered platinum complex AMD473. Br. J. Cancer. 77:1998;366-373.
11. Holford J., Raynaud F.I., Murrer B.A.et al. Chemical, biochemical and pharmacological activity of the novel sterically hindered platinum co-ordination complex, cis-[amminedichloro(2-methylpyridine)] platinum(II) (AMD473). Anticancer Drug Des. 13:1998;1-18.
12. Aebi S., Kurdi-Haidar B., Gordon R.et al. Loss of DNA mismatch repair in acquired resistance to cisplatin. Cancer Res. 56:1996;3087-3090.
13. Branch P., Masson M., Aquilina G., Bignami M., Karran P. Spontaneous development of drug resistance:mismatch repair and p53 defects in resistance to cisplatin in human tumor cells. Oncogene. 19:2000;3138-3145.
14. Holford J., Beale P.J., Boxall F.E., Sharp S.Y., Kelland L.R. Mechanisms of drug resistance to the platinum complex ZD0473 in ovarian cancer cell lines. Eur. J. Cancer. 36:2000;1984-1990.
15. Mistry P., Kelland L.R., Abel G., Sidhar S., Harrap K.R. The relationships between glutathione, glutathione-S-transferase and cytotoxicity of platinum drugs and melphalan in eight human ovarian carcinoma cell lines. Br. J. Cancer. 64:1991;220.
16. Calvert A.H., Thomas H., Colombo N.et al. Phase II clinical study of BBR3464, bifunctional platinum analogue, in patients with advanced ovarian cancer. Proceedings ECCO. 2001;A965.
17. Manzotti C., Pratesi G., Menta E.et al. BBR3464. a novel triplatinum complex, exhibiting a preclinical profile of antitumor efficacy different from cisplatin Clinical Cancer Res. 6:2000;2626-2634.
18. El-akawi Z., Abu-hadid M., Perez R.et al. Altered glutathione metabolism in oxaliplatin resistant ovarian carcinoma cells. Cancer Lett. 105:1996;5-14.
19. Kelland L.R., Mistry P., Abel G.et al. Mechanism-related circumvention of acquired cis-diamminedichloro platinum(II) resistance using two pairs of human ovarian carcinoma cell lines by ammine/amine platinum(IV) dicarboxylates. Cancer Res. 52:1992;3857-3864.
20. Hector S., Bolanowska-Higdon W., Zdanowicz J., Hitt S., Pendyala L. In vitro studies on the mechanisms of oxaliplatin resistance. Cancer Chemother. Pharmacol. 48:2001;398-406.
21. Woynarowski J.M., Chapman W.G., Napier C., Herzig M.C.S., Juniewicz P. Sequence- and region-specificity of oxaliplatin adducts in naked and cellular DNA. Mol. Pharmacol. 54:1998;770-777.
22. Woynarowski J.M., Faivre S., Herzig M.C.S.et al. Oxaliplatin-induced damage of cellular DNA. Mol. Pharmacol. 58:2000;920-927.
23. Scheeff E.D., Briggs J.M., Howell S.B. Molecular modeling of the intrastrand guanine-guanine DNA adducts produced by cisplatin and oxaliplatin. Mol. Pharmacol. 56:1999;633-643.
24. Drummond J.T., Anthoney A., Brown R., Modrich P. Cisplatin and adriamycin resistance are associated with mutLα and mismatch repair deficiency in an ovarian tumor cell line. J. Biol. Chem. 271:1996;19645-19648.
25. Johnson S.W., Ferry K.V., Hamilton T.C. Recent insights into platinum drug resistance in cancer. Drug Resist. Updates. 1:1998;243-254.
26. Behrens B.C., Hamilton T.C., Masuda H.et al. Characterization of a cis-diamminedichloroplatinum(II)-resistant human ovarian carcinoma cell line and its use in the evaluation of platinum analogs. Cancer Res. 47:1987;414-418.
27. O'Neill C.F., Koberle B., Masters J.R.W., Kelland L.R. Gene-specific repair of Pt/DNA lesions and induction of apoptosis by the oral platinum drug JM216 in three human ovarian carcinoma cell lines sensitive and resistant to cisplatin. Br. J. Cancer. 81:1999;1294-1303.
28. Vaisman A., Varchenko M., Umar A.et al. The role of hMLH1, hMSH3, and hMSH6 defects in cisplatin and oxaliplatin resistance. correlation with replicative bypass of platinum-DNA adducts Cancer Res. 58:1998;3579-3585.
29. Beale P.J., Rogers P., Boxall F., Sharp S.Y., Kelland L.R. Bcl-2 family protein expression and platinum drug resistance in ovarian carcinoma. Br. J. Cancer. 82:2000;436-440.
30. Nehme A., Baskaran R., Nebel S.et al. Induction of JNK and c-Abl signalling by cisplatin and oxaliplatin in mismatch repair-proficient and- deficient cells. Br. J. Cancer. 79:1999;1104-1110.
31. Brown R., Hirst G.L., Gallagher W.M.et al. hMLH1 expression and cellular responses of ovarian tumour cells to treatment with cytotoxic anticancer agents. Oncogene. 15:1997;45-52.